Lipodystrophy Clinical Trials

8 recruiting

Frequently Asked Questions

Common questions about Lipodystrophy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 117 of 17 trials

Recruiting
Phase 3

Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy

Generalized Lipodystrophy
Regeneron Pharmaceuticals28 enrolled1 locationNCT07220785
Recruiting

The LD Lync Study - Natural History Study of Lipodystrophy Syndromes

Lipodystrophy (Genetic or Acquired, Non HIV)
University of Michigan500 enrolled4 locationsNCT03087253
Recruiting
Phase 2

Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance

Partial LipodystrophyInsulin Receptor Mutation
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)25 enrolled1 locationNCT05470504
Recruiting

Natural History of Pregnancy and Pregnancy Outcomes in Metreleptin-Treated vs Untreated Subjects With Lipodystrophy

Lipodystrophy
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)90 enrolled1 locationNCT05419037
Recruiting

Feasibility of Adipose Tissue Triglyceride (TG) Labelling in Familial Partial Lipodystrophy (FPLD)

Lipodystrophy
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)14 enrolled1 locationNCT05996536
Recruiting
Phase 3

Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy

Familial Partial Lipodystrophy
Amryt Pharma24 enrolled7 locationsNCT06679270
Recruiting
Phase 3

Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy

Generalized Lipodystrophy
Amryt Pharma15 enrolled12 locationsNCT06502990
Recruiting

MEASuRE: Metreleptin Effectiveness And Safety Registry

Partial LipodystrophyGeneralised Lipodystrophy
Amryt Pharma100 enrolled28 locationsNCT02325674
Recruiting

Registry for Patients With Lipodystrophy

Lipodystrophy AcquiredLipodystrophy Congenital
University of Ulm5,000 enrolled28 locationsNCT03553420
Recruiting
Phase 2

Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024

Lipodystrophy, Partial
University of Michigan32 enrolled1 locationNCT07091734
Recruiting
Not Applicable

Susceptibility to Infectious Diseases in obEsity: an endocRine trAnslational socioLogic Evaluation, "SIDERALE"

LipodystrophyObesityInfections+2 more
Federico II University100 enrolled4 locationsNCT06236932
Recruiting
Phase 4

Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy

Partial Lipodystrophy
Amryt Pharma12 enrolled12 locationsNCT06484868
Recruiting
Not Applicable

Low Energy Diet and Familial Partial Lipodystrophy

LipodystrophyDiabetesDiet Modification
Cambridge University Hospitals NHS Foundation Trust20 enrolled1 locationNCT03900286
Recruiting
Not Applicable

Assess the Possibility of Diagnosing Diabetes and Rediabetes Following Oral Induced Hyperglycemia in Patients With Dunnigan's Partial Familial Lipodystrophy by Replacing 75 g of Glucose With a Standardized Carbohydrate Breakfast and Continuous Interstitial Monitoring Glucose)

Lipodystrophy
Centre Hospitalier Universitaire de la Réunion60 enrolled1 locationNCT05789251
Recruiting

The impact of oscilating-cycloid vibration therapy interventions on skin condition, skin temperature and selected biochemical indices in blood in women with cellulite

Gynoid lipodystrophy
prof. Wanda Pilch100 enrolled1 locationACTRN12619000092190
Recruiting
Phase 4

HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA 001)

LipodystrophyHIV
The University of New South Wales80 enrolled1 locationACTRN12605000662662
Recruiting
Phase 4

Seronegatives And Metabolic Abnormalities Protocol 2 (SAMA 002)

LipodystrophyLipid metabolismGlucose metabolism+1 more
The University of New South Wales50 enrolled1 locationACTRN12605000661673